Michael Kaplitt, M.D., Ph.D.

You are here

Michael Kaplitt, MD, PhD

Dr. Kaplitt combines surgical expertise with advanced training in state-of-the-art stereotactic techniques to provide patients with effective, minimally invasive treatments for degenerative disorders, including Parkinson’s disease, essential tremor, and dystonia. He also uses these methods to provide novel treatments for psychiatric disorders such as obsessive-compulsive disorder as well as for experimental treatment of major depression and drug addiction. In 2016 Dr. Kaplitt became the first in New York to use high-intensity focused ultrasound for the treatment of essential tremor, just weeks after the procedure received FDA approval. In addition, he is an expert in the use of implanted devices for the treatment of medication-resistant complex pain, spasticity and adult hydrocephalus. Dr. Kaplitt is also an expert in various surgical therapies for trigeminal neuralgia as well as novel therapies for more complex craniofacial pain. He is recognized for his contributions by leading medical and patient associations, and has repeatedly been named to Castle Connolly’s America’s Top Doctors and New York Metro Top Doctors and regularly appears on the New York SuperDoctors list. He is a member of the Executive Committee of the American Society for Stereotactic and Functional Neurosurgery, the society for physicians who specialize in this type of surgery, and he is on the editorial board of the journal Stereotactic and Functional Neurosurgery, the primary international journal in this area.

Dr. Kaplitt graduated magna cum laude from Princeton University in 1987 with a degree in Molecular Biology and Russian Studies. He enrolled in the Tri-Institutional M.D.-Ph.D. Program and received his Ph.D. in Molecular Neurobiology in 1993 from The Rockefeller University and his M.D. in 1995 from Cornell Medical College. Following his Neurosurgery residency and chief residency at NewYork-Presbyterian/Weill Cornell, he completed a fellowship in Stereotactic and Functional Neurosurgery with Dr. Andres Lozano at the University of Toronto prior to joining our staff as Assistant Professor of Neurological Surgery in July 2001.

Dr. Kaplitt has pioneered human gene therapy for neurodegenerative disorders, having performed as a student the first rodent study that used the adeno-associated virus (AAV) vehicle for gene transfer to the brain. He performed the world’s first human gene therapy procedure for Parkinson’s disease, and more recently helped to guide the first successful randomized, double-blind, sham-controlled trial of this experimental treatment, which was the first positive trial of this kind for gene therapy in any brain disorder. He is also pioneering the development of novel deep brain stimulation treatments for psychiatric diseases, including refractory drug addiction. Dr. Kaplitt is an internationally recognized expert in the science of gene therapy and molecular neurobiology, and his current focus is to understand molecular disease mechanisms and develop novel molecular therapies for Parkinson’s disease, depression, addiction, and Huntington’s disease. He has published 75 articles and has edited two books on these subjects, with publications from his lab appearing in the most prestigious international journals, including Science, Science Translational Medicine, Nature Genetics, Nature Medicine, Proceedings of the National Academy of Science, and Lancet. His basic science lab has received continuous funding from the National Institutes of Health since 2004 and is also the recipient of major funding from the Department of Defense and several major private foundations.

Dr. Kaplitt is the recipient of numerous awards, including the Young Investigator Award from the American Society for Gene Therapy. In 2004 he was named to Crain’s 40 under 40 list of 40 young New Yorkers.

Request an Appointment | Refer a Patient